RadNetRDNT +4.68%79 3-Year FCF Growth Rate is 34.30% as of Mar. 2026, which is 524% above its 10-year median of 5.50. GuruFocus rates RDNT with a GF Score™ of 79/100 and a GF Value™ of $66.68 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 153 Medical Diagnostics & Research companies, RadNet ranks better than 73.2% on this metric.
During the past 12 months, RadNet's average Free Cash Flow per Share Growth Rate was 27.10% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 34.30% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 2.30% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was -2.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of RadNet was 207.40% per year. The lowest was -65.50% per year. And the median was 5.50% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
RadNet 3-Year FCF Growth Rate Related Terms
RDNT vs SHC, BLLN, TWST: 3-Year FCF Growth Rate Comparison
For the Diagnostics & Research subindustry, RadNet's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RadNet 3-Year FCF Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, RadNet's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where RadNet's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 34.30% mean?
RadNet (RDNT) has a 3-Year FCF Growth Rate of 34.30% as of Mar. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for RadNet and its competitors. This is 524% above median its historical median of 5.50. According to the industry distribution chart, RadNet ranks #41 out of 153 companies in the Medical Diagnostics & Research industry, placing it in the top 26.8%.
Is RadNet's 3-Year FCF Growth Rate too high?
RadNet's current 3-Year FCF Growth Rate of 34.30% is 524% above median its 10-year median of 5.50. The Medical Diagnostics & Research industry median 3-Year FCF Growth Rate is 17.50. RadNet's value of 34.30% is 96% above this industry median. Based on the distribution chart, RadNet ranks #41 out of 153 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, RadNet has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RadNet's 3-Year FCF Growth Rate compare to SHC and BLLN?
According to the Medical Diagnostics & Research industry distribution chart, RadNet ranks #41 out of 153 companies for 3-Year FCF Growth Rate. This puts RadNet in the upper half of its industry. The industry median 3-Year FCF Growth Rate is 17.50. RadNet's value of 34.30% is 96% above this benchmark. While the company's 10-year median is 5.50 vs. the industry median of 17.50, RadNet has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year FCF Growth Rate among Medical Diagnostics & Research companies is 17.50, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RadNet's current 3-Year FCF Growth Rate of 34.30% is 96% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for RadNet and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year FCF Growth Rate is 17.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RadNet's current 3-Year FCF Growth Rate is 34.30%, which is 524% above median its own 10-year median of 5.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RadNet stock overvalued right now?
Based on GuruFocus' analysis, RadNet (RDNT) is currently considered Modestly Undervalued. The stock's GF Value™ is $66.68, compared to a current price of $58.81 — trading 11.8% below its estimated fair value. The current 3-Year FCF Growth Rate is 34.30%, which is 524% above median its 10-year median of 5.50 and 96% above the Medical Diagnostics & Research industry median of 17.50. RadNet's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For RadNet (RDNT), the current 3-Year FCF Growth Rate is 34.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RadNet (RDNT) Overvalued in 2026?
Based on GuruFocus' analysis, RadNet stock appears to be undervalued.
The current stock price of $58.81 is trading 11.8% below its estimated GF Value™ of $66.68.
GuruFocus considers RadNet to be Modestly Undervalued.
Key valuation signals for RDNT:
3-Year FCF Growth Rate: 34.30% (524% above median its 10-year median of 5.50)
GF Value™: $66.68 vs. price of $58.81 (11.8% below fair value)
Industry Position: 96% above the Medical Diagnostics & Research median (#41 of 153)
No single metric tells the full story. See the RDNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.
79GF Score
Get the complete analysis for RDNT
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDNT has been successfully added to your 